Cover Image
Market Research Report

Breast Cancer Drug - Global Market Outlook (2017-2026)

Published by Stratistics Market Research Consulting Product code 907650
Published Content info 154 Pages
Delivery time: 2-3 business days
Price
Back to Top
Breast Cancer Drug - Global Market Outlook (2017-2026)
Published: July 19, 2019 Content info: 154 Pages
Description

According to Stratistics MRC, the Global Breast Cancer Drug Market is accounted for $14.75 billion in 2017 and is expected to reach $43.27 billion by 2026 growing at a CAGR of 12.7% during the forecast period. High prevalence of breast cancer, growing R&D investments and rising healthcare expenditure and awareness are some of the key factors influence market growth. However, stringent regulatory guidelines and expiry of patented drugs is restraining the market growth.

Breast cancer is most commonly diagnosed cancer in women worldwide and also is one of the leading causes of death. Breast cancer is a disease where uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Breast cancer is the result of uncontrolled cell division of breast cells, most commonly cells of breast lobule and ducts.

Based on Drug, Chemotherapy Drugs segment growth is due to development in the fields of drug delivery and oncology, and increased government funding and initiative to create awareness about cancer diagnosis and treatment. By Geography, North America is going to have a lucrative growth due to prevalence of chronic diseases, growing focus of global pharmaceutical companies in this region.

Some of the key players profiled in the Breast cancer drug Market include Novartis AG, Celgene Corporation, Janssen Global Services LLC, Onyx Pharmaceuticals Inc., AbbVie, Inc., Eli Lilly and Company, Celldex Therapeutics, BioNumerik Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc., Genzyme Corporation, MacroGenics, Inc., F. Hoffmann-La Roche Ltd. and Biocon.

Procedures Covered:

  • Mitotic inhibitor
  • Aromatase inhibitor
  • Hormonal rec
  • HER2 inhibitor
  • Anti-metabolites
  • CDK 4/6 inhibitor

Drugs Covered:

  • Targeted Therapy Drugs
  • Chemotherapy Drugs
  • Hormone Therapy Drugs
  • Other Drugs

Drugs Covered:

  • Clinics
  • Online Pharmacies
  • Ambulatory Surgical centers
  • Hospitals
  • Retail Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Drug Market, By Type

  • 5.1 Introduction
  • 5.2 Mitotic Inhibitor
  • 5.3 Aromatase Inhibitor
  • 5.4 Hormonal rec
  • 5.5 HER2 Inhibitor
  • 5.6 Anti-Metabolites
  • 5.7 CDK 4/6 Inhibitor

6 Global Breast Cancer Drug Market, By Drug

  • 6.1 Introduction
  • 6.2 Targeted Therapy Drugs
    • 6.2.1 Ado-Trastuzumab Emtansine
    • 6.2.2 Neratinib
    • 6.2.3 Monoclonal Antibodies (mAbs)
      • 6.2.3.1 Bevacizumab
      • 6.2.3.2 Trastuzumab
      • 6.2.3.3 Other Monoclonal Antibodies (mAbs)
    • 6.2.4 Lapatinib
    • 6.2.5 Tyrosine kinase inhibitors
  • 6.3 Chemotherapy Drugs
    • 6.3.1 Antimetabolites
      • 6.3.1.1 Capecitabine
      • 6.3.1.2 Gemcitabine
      • 6.3.1.3 Fluorouracil
    • 6.3.2 Anthracyclines
      • 6.3.2.1 Epirubicin
      • 6.3.2.2 Doxorubicin
    • 6.3.3 Alkylating Agents
    • 6.3.4 Neoadjuvant Chemotherapy
    • 6.3.5 Adjuvant Chemotherapy
    • 6.3.6 Taxanes
      • 6.3.6.1 Docetaxel
      • 6.3.6.2 Paclitaxel
    • 6.3.7 Advanced Breast Cancer
    • 6.3.8 Epothilones
  • 6.4 Hormone Therapy Drugs
    • 6.4.1 Ecstasy and Related Drug (ERD)
    • 6.4.2 Selective Estrogen-Receptor Modulators (SERMs)
      • 6.4.2.1 Tamoxifen
      • 6.4.2.2 Toremifene
      • 6.4.2.3 Raloxifene
    • 6.4.3 Aromatase Inhibitors
      • 6.4.3.1 Anastrozole
      • 6.4.3.2 Letrozole
      • 6.4.3.3 Megestrol
    • 6.4.5 Luteinising Hormone-Releasing Hormone
    • 6.4.6 Other Hormonal Therapies
      • 6.4.6.1 Goserelin Acetate
      • 6.4.6.2 Fulvestrant
      • 6.4.6.3 Fluoxymesterone
  • 6.5 Other Drugs

7 Global Breast Cancer Drug Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Clinics
  • 7.3 Online Pharmacies
  • 7.4 Ambulatory Surgical Centers
  • 7.5 Hospitals
  • 7.6 Retail Pharmacies

8 Global Breast Cancer Drug Market, By Drug

  • 8.1 North America
    • 8.1.1 US
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 Germany
    • 8.2.2 France
    • 8.2.3 Italy
    • 8.2.4 UK
    • 8.2.5 Spain
  • 8.3 Asia Pacific
    • 8.3.1 Japan
    • 8.3.2 China
    • 8.3.3 India
    • 8.3.4 Australia
    • 8.3.5 New Zealand
    • 8.3.6 Rest of Asia Pacific
  • 8.4 South America
    • 8.4.1 Argentina
    • 8.4.2 Brazil
    • 8.4.3 Venezuela
    • 8.4.4 Chile
    • 8.4.5 Peru
  • 8.5 Middle East & Africa
    • 8.5.1 UAE
    • 8.5.2 Saudi Arabia
    • 8.5.3 Qatar
    • 8.5.4 Iran
    • 8.5.5 South Africa
    • 8.5.6 Rest of MEA

9 Vendor Landscaping

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiles

  • 10.1 Novartis AG
  • 10.2 Celgene Corporation
  • 10.3 Janssen Global Services LLC
  • 10.4 Onyx Pharmaceuticals Inc.
  • 10.5 AbbVie, Inc.
  • 10.6 Eli Lilly and Company
  • 10.7 Celldex Therapeutics
  • 10.8 BioNumerik Pharmaceuticals, Inc.
  • 10.9 AstraZeneca
  • 10.10 Merck & Co., Inc.
  • 10.11 Genzyme Corporation
  • 10.12 MacroGenics, Inc.
  • 10.13 F. Hoffmann-La Roche Ltd.
  • 10.14 Biocon

List of Tables

  • 1 Global Breast Cancer Drug Market Outlook, By Region (2016-2026)(US $MN)
  • 2 Global Breast Cancer Drug Market Outlook, By Type (2016-2026)(US $MN)
  • 3 Global Breast Cancer Drug Market Outlook, By Mitotic Inhibitor (2016-2026)(US $MN)
  • 4 Global Breast Cancer Drug Market Outlook, By Aromatase Inhibitor (2016-2026)(US $MN)
  • 5 Global Breast Cancer Drug Market Outlook, By Hormonal rec (2016-2026)(US $MN)
  • 6 Global Breast Cancer Drug Market Outlook, By HER2 Inhibitor (2016-2026)(US $MN)
  • 7 Global Breast Cancer Drug Market Outlook, By Anti-Metabolites (2016-2026)(US $MN)
  • 8 Global Breast Cancer Drug Market Outlook, By CDK 4/6 Inhibitor (2016-2026)(US $MN)
  • 9 Global Breast Cancer Drug Market Outlook, By Drug (2016-2026)(US $MN)
  • 10 Global Breast Cancer Drug Market Outlook, By Targeted Therapy Drugs (2016-2026)(US $MN)
  • 11 Global Breast Cancer Drug Market Outlook, By Ado-Trastuzumab Emtansine (2016-2026)(US $MN)
  • 12 Global Breast Cancer Drug Market Outlook, By Neratinib (2016-2026)(US $MN)
  • 13 Global Breast Cancer Drug Market Outlook, By Monoclonal Antibodies (mAbs) (2016-2026)(US $MN)
  • 14 Global Breast Cancer Drug Market Outlook, By Lapatinib (2016-2026)(US $MN)
  • 15 Global Breast Cancer Drug Market Outlook, By Tyrosine kinase inhibitors (2016-2026)(US $MN)
  • 16 Global Breast Cancer Drug Market Outlook, By Chemotherapy Drugs (2016-2026)(US $MN)
  • 17 Global Breast Cancer Drug Market Outlook, By Antimetabolites (2016-2026)(US $MN)
  • 18 Global Breast Cancer Drug Market Outlook, By Anthracyclines (2016-2026)(US $MN)
  • 19 Global Breast Cancer Drug Market Outlook, By Alkylating Agents (2016-2026)(US $MN)
  • 20 Global Breast Cancer Drug Market Outlook, By Neoadjuvant Chemotherapy (2016-2026)(US $MN)
  • 21 Global Breast Cancer Drug Market Outlook, By Adjuvant Chemotherapy (2016-2026)(US $MN)
  • 22 Global Breast Cancer Drug Market Outlook, By Taxanes (2016-2026)(US $MN)
  • 23 Global Breast Cancer Drug Market Outlook, By Advanced Breast Cancer (2016-2026)(US $MN)
  • 24 Global Breast Cancer Drug Market Outlook, By Epothilones (2016-2026)(US $MN)
  • 25 Global Breast Cancer Drug Market Outlook, By Hormone Therapy Drugs (2016-2026)(US $MN)
  • 26 Global Breast Cancer Drug Market Outlook, By Ecstasy and Related Drug (ERD) (2016-2026)(US $MN)
  • 27 Global Breast Cancer Drug Market Outlook, By Selective Estrogen-Receptor Modulators (SERMs) (2016-2026)(US $MN)
  • 28 Global Breast Cancer Drug Market Outlook, By Aromatase Inhibitors (2016-2026)(US $MN)
  • 29 Global Breast Cancer Drug Market Outlook, By Luteinising Hormone-Releasing Hormone (2016-2026)(US $MN)
  • 30 Global Breast Cancer Drug Market Outlook, By Other Hormonal Therapies (2016-2026)(US $MN)
  • 31 Global Breast Cancer Drug Market Outlook, By Distribution Channel (2016-2026)(US $MN)
  • 32 Global Breast Cancer Drug Market Outlook, By Clinics (2016-2026)(US $MN)
  • 33 Global Breast Cancer Drug Market Outlook, By Online Pharmacies (2016-2026)(US $MN)
  • 34 Global Breast Cancer Drug Market Outlook, By Ambulatory Surgical Centers (2016-2026)(US $MN)
  • 35 Global Breast Cancer Drug Market Outlook, By Hospitals (2016-2026)(US $MN)
  • 36 Global Breast Cancer Drug Market Outlook, By Retail Pharmacies (2016-2026)(US $MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Back to Top